COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a psychological well being care firm devoted to accelerating affected person entry to evidence-based innovation in psychological well being, has fashioned a long-term strategic partnership to launch The Centre for Psychological Well being Analysis and Innovation (“the Centre”) to speed up psychedelic analysis and develop new fashions of look after psychological well being within the UK.
Along with South London and Maudsley NHS Basis Belief (SLaM), the most important psychological well being belief within the UK Nationwide Well being Service (NHS) and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s School London, this pioneering collaboration will present affected person entry to innovative analysis research in a number of areas of excessive unmet want in psychological well being.
The Centre will speed up analysis of rising psychedelic therapies, help therapist coaching and certification, consider real-world proof, and prototype digital applied sciences to allow personalised, predictive and preventative care fashions.
George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, mentioned, “In 2021, the UK Authorities included psychological well being care as a core pillar of its Life Sciences Imaginative and prescient – a sign of how important a problem that is turning into. We’re grateful to have the ability to play an element on this, and to be working with SLaM and the IoPPN, UK leaders in affected person care and analysis in psychological well being. The Centre will speed up the combination of modern psychedelic therapies into the NHS following regulatory approval and reimbursement. It’s a key a part of our technique to work with well being methods to develop modern evidence-based therapies, and guarantee they attain those that would possibly profit from them as rapidly as potential.”
Analysis will initially give attention to COMPASS’s investigational COMP360 psilocybin remedy and supportive applied sciences, and also will cowl different novel therapeutic approaches being researched and developed by COMPASS, in areas of serious unmet psychological well being want together with treatment-resistant melancholy (TRD), post-traumatic stress dysfunction (PTSD) and anorexia nervosa.
The ambition is for the Centre to be a beacon of modern psychological well being care fashions, and assist encourage and speed up the event of such public-private partnerships amongst trade sponsors, educational investigators and the NHS beneath the Psychological Well being Mission throughout the new UK Authorities Life Sciences Imaginative and prescient. The Centre will initially be positioned at Maudsley Hospital, London, whereas state-of-the-art services are constructed inside a 200 acre woodland at Bethlem Royal Hospital, London. This devoted and purpose-built house for late-stage scientific trials will probably be managed by main scientific investigators with in depth expertise in conducting psychedelic scientific trials, and can present entry to COMP360 psilocybin remedy to an estimated 650-700 sufferers over a five-year time period.
David Bradley, Chief Government of South London and Maudsley NHS Basis Belief, mentioned, “We’re seeing a speedy progress within the variety of individuals with psychological well being care wants, in South London and throughout the UK. We’re proud to proceed our legacy of innovation and analysis by partnering with COMPASS Pathways to immediately translate analysis into healthcare therapy and considerably enhance care in our communities.”
Professor Allan Younger, Head of Educational Psychiatry at King’s IoPPN, mentioned, “This new Centre is all about placing sufferers first. The collaboration with COMPASS Pathways will give attention to creating new and efficient therapies, in addition to contemplating the affected person expertise in the true world. We hope it would pave the way in which for the way analysis and improvements partnerships are developed sooner or later.”
-Ends-
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a psychological well being care firm devoted to accelerating affected person entry to evidence-based innovation in psychological well being. Our focus is on enhancing the lives of those that are struggling with psychological well being challenges and who will not be helped by present remedies. We’re pioneering the event of a brand new mannequin of psilocybin remedy, wherein our proprietary formulation of artificial psilocybin, COMP360, is run together with psychological help. COMP360 has been designated a Breakthrough Remedy by the US Meals and Drug Administration (FDA), for treatment-resistant melancholy (TRD), and we’ve got accomplished a part IIb scientific trial of psilocybin remedy for TRD, in 22 websites throughout Europe and North America. This was the most important randomised, managed, double-blind psilocybin remedy scientific trial ever carried out, and our topline knowledge confirmed a statistically vital (p www.compasspathways.com
Availability of different details about COMPASS Pathways
Traders and others ought to word that we talk with our buyers and the general public utilizing our web site (www.compasspathways.com), our investor relations web site (ir.compasspathways.com), and on social media (LinkedIn), together with however not restricted to investor shows and investor reality sheets, US Securities and Trade Fee filings, press releases, public convention calls and webcasts. The data that we put up on these channels and web sites might be deemed to be materials info. In consequence, we encourage buyers, the media, and others keen on us to evaluate the data that’s posted on these channels, together with the investor relations web site, regularly. This checklist of channels could also be up to date on occasion on our investor relations web site and will embrace extra social media channels. The contents of our web site or these channels, or every other web site which may be accessed from our web site or these channels, shall not be deemed integrated by reference in any submitting beneath the Securities Act of 1933.
Ahead-looking statements
This press launch incorporates forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995, as amended. In some circumstances, forward-looking statements might be recognized by terminology akin to “could”, “would possibly”, “will”, “may”, “would”, “ought to”, “anticipate”, “intend”, “plan”, “goal”, “anticipate”, “imagine”, “ponder”, “estimate”, “predict”, “potential”, “proceed” and “ongoing,” or the destructive of those phrases or different comparable terminology, though not all forward-looking statements include these phrases. Ahead-looking statements embrace specific or implied statements regarding, amongst different issues, the protection or efficacy of psilocybin remedy, together with COMP360, as a therapy for melancholy, COMPASS’s enterprise technique and targets, together with its means to launch and commercialise merchandise, COMPASS’s expectations and plans relating to the Centre, COMPASS’s expectations for the timing of its pivotal part III programme and the potential for that or different trials to help regulatory filings and approvals, COMPASS’s means to proceed to advance its analysis or develop plans to carry its product candidates to sufferers, and COMPASS’s expectations relating to the advantages of psilocybin remedy. The forward-looking statements on this press launch are neither guarantees nor ensures, and you shouldn’t place undue reliance on these forward-looking statements as a result of they contain recognized and unknown dangers, uncertainties, and different components, lots of that are past COMPASS’s management and which may trigger precise outcomes, ranges of exercise, efficiency or achievements to vary materially from these expressed or implied by these forward-looking statements.
These dangers, uncertainties, and different components embrace, amongst others: preclinical analysis and scientific growth is prolonged and unsure, and subsequently our preclinical research and scientific trials could also be delayed or terminated, or could by no means advance to or within the clinic; and people dangers and uncertainties described beneath the heading “Danger Elements” in COMPASS’s annual report on Type 10-Ok filed with the US Securities and Trade Fee (SEC) on 24 February 2022 and in subsequent filings made by COMPASS with the SEC, which can be found on the SEC’s web site at www.sec.gov. Besides as required by legislation, COMPASS disclaims any intention or duty for updating or revising any forward-looking statements contained on this press launch within the occasion of recent info, future developments or in any other case. These forward-looking statements are based mostly on COMPASS’s present expectations and communicate solely as of the date hereof.
About King’s School London and the Institute of Psychiatry, Psychology & Neuroscience
King’s School London is among the prime 35 UK universities on the planet and one of many prime 10 in Europe (QS World College Rankings, 2020/21) and among the many oldest in England. King’s has greater than 31,000 college students (together with greater than 12,800 postgraduates) from some 150 international locations worldwide, and eight,500 workers. King’s has an excellent repute for world-class instructing and cutting-edge analysis. The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s is the premier centre for psychological well being and associated neurosciences analysis in Europe. It produces extra extremely cited outputs (prime 1% citations) on psychological well being than every other centre (SciVal 2019) and on this metric we’ve got risen from sixteenth (2014) to 4th (2019) on the planet for extremely cited neuroscience outputs. World-leading analysis from the IoPPN has made, and continues to make, an affect on how we perceive, forestall and deal with psychological sickness and different circumstances that have an effect on the mind.
www.kcl.ac.uk/ioppn @KingsIoPPN
About South London and Maudsley NHS Basis Belief
South London and Maudsley NHS Basis Belief is a big and sophisticated multi-site supplier of psychological well being providers – offering the widest vary of NHS psychological well being providers within the UK. We goal to make a distinction to individuals’s lives by in search of excellence in all areas of psychological well being and wellbeing. Our 6,000 workers serve an area inhabitants of 1.3 million individuals and we provide greater than 260 providers together with inpatient wards, outpatient and neighborhood providers throughout Lambeth, Lewisham, Southwark and Croydon. We additionally present substance misuse providers for people who find themselves hooked on medication and alcohol. In addition to serving the communities of south London, we offer greater than 20 specialist providers for youngsters and adults throughout the UK together with perinatal providers, consuming problems, psychosis and autism.
Enquiries
Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Traders: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
Movies accompanying this announcement can be found at:
https://www.youtube.com/embed/rdg2EncqE4I
https://www.youtube.com/embed/pTHytMEft48
